Chronic inflammatory bowel conditions like ulcerative colitis become increasingly common throughout adulthood, but this condition is being noticed more often in the 60-and-older crowd. Research ...

Johnson & Johnson (J&J) announced data from the phase 3 ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC) at ...